Stryker (SYK) Cyberattack Puts Its Undervalued Narrative To The Test

Stryker (SYK) is under scrutiny after a cyberattack linked to Iranian hackers triggered factory resets on over 200,000 medical devices worldwide, temporarily halting order processing and production in dozens of countries.

See our latest analysis for Stryker.

At a share price of $316.44, Stryker has seen its 1 day share price return rise 1.73%, but the year to date share price return is down 9.12% and the 1 year total shareholder return has declined 18.22%. This suggests recent concerns around the cyberattack and softer capital equipment spending are weighing more heavily than the company’s longer term 3 year and 5 year total shareholder returns of 10.65% and 28.85%.

If this cybersecurity shock has you reassessing where growth and risk sit in your portfolio, it could be worth scanning for other healthcare technology stories through the 40 healthcare AI stocks.

Bulls argue Stryker’s scale and growth track record outweigh a one off cyber shock, while bears see a richly priced stock exposed to weaker hospital budgets and rising competition. Which side does the valuation actually support next?

Most Popular Narrative: 18% Undervalued

Stryker is trading at $316.44 compared with a widely followed fair value narrative of $386.80. This frames the current pullback as a valuation gap rather than a broken story.

Robust innovation pipeline, particularly in robotic-assisted surgery (Mako platform) and next-generation devices, is driving greater market share, higher average selling prices, and service revenues, which is expected to accelerate both revenue and margin expansion over time.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that confidence in Stryker? The narrative leans on steady revenue compounding, rising margins, and a future earnings base that has to clear a high bar. The exact hurdle rates, growth path, and profit assumptions are where the story really gets interesting.

Result: Fair Value of $386.80 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that underpriced story for Stryker also depends on smooth execution, and prolonged regulatory delays or sustained supply chain disruption could quickly challenge those assumptions.

Find out about the key risks to this Stryker narrative.

Another View: Stryker Looks Expensive On P/E

While the SWS DCF model suggests Stryker is trading at a discount to its estimated future cash flow value of $400.68, the P/E picture is less forgiving. At 36.4x, the stock trades above the US Medical Equipment industry on 26.1x, peers on 27.6x, and even its own 34.3x fair ratio; this points to valuation risk if growth or margins fall short.

Put simply, the DCF flags upside if Stryker delivers on its long term forecasts, but the rich earnings multiple leaves less room for disappointment. Which lens do you rely on more when sizing your position? See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Seeing both optimism and concern around Stryker in this article, it makes sense to move quickly, weigh the data for yourself, and review the 4 key rewards and 2 important warning signs

Looking for more investment ideas beyond Stryker?

If Stryker has sharpened your focus on quality and risk, do not stop here. Broaden your watchlist now with targeted stock ideas built from hard data.

• Target long term value potential by scanning companies that look mispriced on fundamentals using the 47 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks with resilient cash flows in the 10 dividend fortresses.
• Dial down portfolio risk by filtering for sturdier businesses and balance sheets through the 78 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com